Daily Stock Analysis, ENTA, Enanta Pharmaceuticals Inc, priceseries

Enanta Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
82.43
Close
82.49
High
84.37
Low
81.69
Previous Close
82.00
Daily Price Gain
0.49
YTD High
106.80
YTD High Date
Mar 4, 2019
YTD Low
68.67
YTD Low Date
Jan 2, 2019
YTD Price Change
10.13
YTD Gain
14.00%
52 Week High
123.70
52 Week High Date
Jul 23, 2018
52 Week Low
64.08
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-33.11
52 Week Gain
-28.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 12. 2017
31.15
Jul 7. 2017
36.13
18 Trading Days
15.98%
Link
LONG
Aug 24. 2017
39.31
Sep 12. 2017
41.87
12 Trading Days
6.51%
Link
LONG
Sep 27. 2017
44.53
Oct 16. 2017
47.62
13 Trading Days
6.94%
Link
LONG
Jan 16. 2018
62.76
Feb 8. 2018
83.52
17 Trading Days
33.08%
Link
LONG
Jun 29. 2018
115.90
Jul 16. 2018
121.72
10 Trading Days
5.02%
Link
LONG
Jan 30. 2019
79.02
Mar 6. 2019
99.92
24 Trading Days
26.45%
Link
Company Information
Stock Symbol
ENTA
Exchange
NasdaqGS
Company URL
http://www.enanta.com
Company Phone
617 607 0800
CEO
Jay R. Luly
Headquarters
Massachusetts
Business Address
500 ARSENAL STREET, WATERTOWN, MA 02472
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001177648
About

Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It focuses on the following disease targets: Hepatitis C virus, Hepatitis B virus, Non-alcoholic Steatohepatitis, and Respiratory syncytial virus. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Description

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.